For rectal and head and neck cancers, direct pO2 measurements have established a significant intratumoral hypoxic fraction. This is of great clinical significance as tumor hypoxia is thought to negatively influence cancer response to chemoradiation (CMT), a major treatment component for these tumors. However, current methods for assessing tumor hypoxia are limited by their invasive nature and associated sampling errors due to heterogeneity of intratumoral oxygenation. The focus of this project is the clinical evaluation of non-invasive imaging of global tumor hypoxia via positron emission tomography (PET) in patients with rectal and head and neck cancers. We propose to evaluate two hypoxia tracers conjugated with positron-emitting radioisotopes: 18F-FMISO and 124I- IAZGP. Given their different characteristics, difficult-to-predict pharmacokinetics, and possible disease and anatomyrelated influences, we will test them in these two tumor types and identify the optimal tumor-specific tracer. Therefore, the Specific Aims of RP4 are: I. To identify the optimal hypoxia tracer for PET imaging of locally advanced rectal cancer and head and neck cancers. 100 patients of each disease site will be studied, Each patient will be imaged with 18F-FMISOand 124I-IAZGP. The images will be evaluated in terms of image quality and prognostic value of treatment outcome. II. To correlate, in rectal cancer, global tumor hypoxia assessed by PET imaging with that assessed by direct pO2 measurements using polarographic electrodes and IHC analysis of hypoxia-related proteins. We believe that these series of clinical studies will demonstrate the utility of PET hypoxia imaging and enhance the management of patients with rectal and head and neck cancers.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA115675-04
Application #
7798054
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2009-04-01
Budget End
2010-03-31
Support Year
4
Fiscal Year
2009
Total Cost
$249,189
Indirect Cost
Name
Sloan-Kettering Institute for Cancer Research
Department
Type
DUNS #
064931884
City
New York
State
NY
Country
United States
Zip Code
10065
Leftin, Avigdor; Koutcher, Jason A (2018) Quantification of Nanoparticle Enhancement in Polarized Breast Tumor Macrophage Deposits by Spatial Analysis of MRI and Histological Iron Contrast Using Computer Vision. Contrast Media Mol Imaging 2018:3526438
Dong, Jun; Ren, Yufeng; Zhang, Tian et al. (2018) Inactivation of DNA-PK by knockdown DNA-PKcs or NU7441 impairs non-homologous end-joining of radiation-induced double strand break repair. Oncol Rep 39:912-920
Dong, Jun; Zhang, Tian; Ren, Yufeng et al. (2017) Inhibiting DNA-PKcs in a non-homologous end-joining pathway in response to DNA double-strand breaks. Oncotarget 8:22662-22673
Leftin, Avigdor; Zhao, Huiyong; Turkekul, Mesru et al. (2017) Iron deposition is associated with differential macrophage infiltration and therapeutic response to iron chelation in prostate cancer. Sci Rep 7:11632
Zanzonico, Pat B (2016) The Neglected Side of the Coin: Quantitative Benefit-risk Analyses in Medical Imaging. Health Phys 110:301-4
Shaffer, Travis M; Harmsen, Stefan; Khwaja, Emaad et al. (2016) Stable Radiolabeling of Sulfur-Functionalized Silica Nanoparticles with Copper-64. Nano Lett 16:5601-4
Simões, Rui V; Serganova, Inna S; Kruchevsky, Natalia et al. (2015) Metabolic plasticity of metastatic breast cancer cells: adaptation to changes in the microenvironment. Neoplasia 17:671-84
Sun, Xiaorong; Ackerstaff, Ellen; He, Fuqiu et al. (2015) Visualizing the antivascular effect of bortezomib on the hypoxic tumor microenvironment. Oncotarget 6:34732-44
Shaffer, Travis M; Wall, Matthew A; Harmsen, Stefan et al. (2015) Silica nanoparticles as substrates for chelator-free labeling of oxophilic radioisotopes. Nano Lett 15:864-8
Hsiao, Hung Tsung; Xing, Ligang; Deng, Xuelong et al. (2014) Hypoxia-targeted triple suicide gene therapy radiosensitizes human colorectal cancer cells. Oncol Rep 32:723-9

Showing the most recent 10 out of 66 publications